tbuckley/cabot-search huggingface dataset:
The association between breast cancer patients’ general health perception and organizational characteristics of the hospital
Authors: H. Pfaff, P. Steffen, A. Nitzsche, C. Kowalski
Journal: Journal of Clinical Oncology (2009)

e17523 Background: The purpose of this study is to investigate the impact of organizational characteristics of the hospital on general health perception in postoperative primary breast cancer patients after discharge from hospital. Methods: Patients undergoing treatment for primary breast cancer in all certified breast centers in North Rhine-Westphalia (Germany) were invited to self-administer a questionnaire on health-related quality of life after discharge. Survey period was February to July 2007. 3,285 patients from 94 hospitals returned the questionnaire. The data were supplemented by disease and treatment characteristics reported by the oncologists (e.g. TNM-classification, type of surgery). Patient data were combined with information on hospital characteristics provided by hospital administrators. A multilevel analysis was applied to analyse the impact of organizational characteristics of the hospital (no. of annual breast cancer surgeries, breast care nurses employed, teaching hospital) on general health perception as reported by the breast cancer patients after discharge. Analyses were controlled for sociodemographic variables (age, marital status, education), type of surgery (mastectomy vs. BCT), and severity of disease (TNM-classification). Results: In the multilevel analysis performed organizational characteristics of the hospital do not contribute to patients’ general health after discharge. Only the variable “breast care nurses employed” is close to being positively associated with better general health at p &lt; 0.05. In the model lymph node status (p &lt; 0.05), metastases (p &lt; 0.05), type of surgery (p &lt; 0.01), age (p &lt; 0.001), and education (p &lt; 0.01) contribute to the explanation of the variance in general health perception. Conclusions: In the breast centers under investigation organizational characteristics of the hospital do not have an impact on primary breast cancer patients’ general health after hospital discharge. A possible reason is the high degree to which the treatment process itself is standardized. No significant financial relationships to disclose.
P1.09-13 Prognostic Value of TMPRSS4 Expression and Its Role as Diagnostic Biomarker by Liquid Biopsy in Early Stage NSCLC
Authors: F. Exposito, M. Villalba, M.J. Pajares, C. Sainz, A. Remirez, E. Jantus, C. Camps, L. Montuenga, R. Pio, C. De Andrea, A. Calvo
Journal: Journal of Thoracic Oncology (2019)
MA09.02 In Vivo, Ex Vivo and Early Clinical Activity of EGFR Monoclonal Antibody and Osimertinib in EGFR Exon 20 Insertion NSCLC
Authors: J. Riess, N. Floch, P. Mack, M. Martin, D. Vang, P. Smith, D. Cross, M. Cheng, J. Keck, S. Groshen, M. Rabin, S. Padda, G. Oxnard, J. Sands, K. Ramchandran, M. Koczywas, J. Moscow, P. Jänne, P. Lara, E. Newman, D. Gandara
Journal: Journal of Thoracic Oncology (2019)
MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up
Authors: Y. Wu, Y. Cheng, J. Zhou, S. Lu, Y. Zhang, J. Zhao, D. Kim, R. Soo, S. Kim, H. Pan, Y. Chen, C. Chian, X. Liu, D. Tan, R. Bruns, J. Straub, A. Johne, J. Scheele, K. Park, J.C. Yang
Journal: Journal of Thoracic Oncology (2019)
Royal college urged to end use of “pejorative” term salaried GP
Authors: Abi Rimmer
Journal: BMJ (2019)

Delegates at the annual conference of the Royal College of General Practitioners in Liverpool applauded a colleague who called for an end to the use of the term “salaried” to describe doctors employed by general practices.

Sally Ross, a GP in Portsmouth, told a discussion on 25 October, “I’ve never heard a surgeon or a respiratory physician describe themselves as salaried.

“It is a pejorative term. I’m an appraiser, and I see a lot of salaried GPs who would love to contribute more but because of their contractual status they don’t. Please will the college start from tomorrow to abandon the term?”

Responding to the question, Dublin GP Austin O’Carroll said that there could be a link between …
P2.14-43 Cost-Effectiveness of 1st-Line Treatment EGFR-TKIs for Advanced NSCLC Patients Harboring EGFR Mutation in Mexico
Authors: L.A. Ramírez Tirado, S. Guzmán, C. Goycochea-Robles, F. Barrón, L. Cabrera-Miranda, D. Flores-Estrada, O.G. Arrieta
Journal: Journal of Thoracic Oncology (2019)
Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy
Authors: B. Douglas Smith, Jun Liu, Dominick Latremouille-Viau, Zhou Zhou, Annie Guerin, Daniel Fernandez, Dingdong Yi, Xufei Wang, Eric Q Wu, Shivani K Mhatre, Christopher H Keir, Lei Chen
Journal: Blood (2014)
P1.12-15 PET Imaging of [18F]PARP Inhibitor as a Pharmacodynamic Biomarker of Talazoparib in Small Cell Lung Cancer PDXs
Authors: B. Lok, J. Laird, B. Carney, S. Kossatz, E. De Stanchina, T. Reiner, J. Poirier, C. Rudin
Journal: Journal of Thoracic Oncology (2019)
Personal Life Events—A Promising Dimension for Psychiatry in Electronic Health Records
Authors: Myrna M. Weissman, Jyotishman Pathak, Ardesheer Talati
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
P1.03-15 Non-Invasive Detection of Secondary Resistance Mutations in ALK-Positive NSCLC Patients by Next-Generation Sequencing
Authors: E. Sánchez Herrero, M. Barquin, V. Calvo De Juan, M. Auglyte, R. Garcia Campelo, J.M. Sánchez, M. Domine, B. Massuti, E. Jantus, C. Camps, N. Reguart, M. Provencio, A. Romero
Journal: Journal of Thoracic Oncology (2019)
IDOL regulates systemic energy balance through control of neuronal VLDLR expression
Authors: Stephen D. Lee, Christina Priest, Mikael Bjursell, Jie Gao, Douglas V. Arneson, In Sook Ahn, Graciel Diamante, J. Edward van Veen, Megan G. Massa, Anna C. Calkin, Jason Kim, Harriet Andersén, Prashant Rajbhandari, Michelle Porritt, Alba Carreras, Andrea Ahnmark, Frank Seeliger, Ingela Maxvall, Pernilla Eliasson, Magnus Althage, Peter Åkerblad, Daniel Lindén, Tracy A. Cole, Richard Lee, Helen Boyd, Mohammad Bohlooly-Y, Stephanie M. Correa, Xia Yang, Peter Tontonoz, Cynthia Hong
Journal: Nature Metabolism (2019)
On the valid publication of names of mycobacteria
Authors: Aharon Oren, Martha E. Trujillo
Journal: European Respiratory Journal (2019)

<b>The message presented by Tortoli and co-workers in their paper "Same meat, different gravy: ignore the new names of mycobacteria" is correct, but the paper contains many errors and misconceptions about the functioning of the Prokaryotic Code and the IJSEM</b>http://bit.ly/2YD9u6s
Tumor Mutation Burden—From Doubts to Concerns
Authors: Mary A. Wood, Abhinav Nellore, Reid F. Thompson
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A Basal Forebrain-Cingulate Circuit in Macaques Decides It Is Time to Act
Authors: Nima Khalighinejad, Alessandro Bongioanni, Lennart Verhagen, Davide Folloni, David Attali, Jean-Francois Aubry, Jerome Sallet, Matthew F.S. Rushworth
Journal: Neuron (2019)

The medial frontal cortex has been linked to voluntary action, but an explanation of why decisions to act emerge at particular points in time has been lacking. We show that, in macaques, decisions about whether and when to act are predicted by a set of features defining the animal's current and past context; for example, respectively, cues indicating the current average rate of reward and recent previous voluntary action decisions. We show that activity in two brain areas-the anterior cingulate cortex and basal forebrain-tracks these contextual factors and mediates their effects on behavior in distinct ways. We use focused transcranial ultrasound to selectively and effectively stimulate deep in the brain, even as deep as the basal forebrain, and demonstrate that alteration of activity in the two areas changes decisions about when to act.
RaGOO: fast and accurate reference-guided scaffolding of draft genomes
Authors: Michael Alonge, Sebastian Soyk, Srividya Ramakrishnan, Xingang Wang, Sara Goodwin, Fritz J. Sedlazeck, Zachary B. Lippman, Michael C. Schatz
Journal: Genome biology (2019)

We present RaGOO, a reference-guided contig ordering and orienting tool that leverages the speed and sensitivity of Minimap2 to accurately achieve chromosome-scale assemblies in minutes. After the pseudomolecules are constructed, RaGOO identifies structural variants, including those spanning sequencing gaps. We show that RaGOO accurately orders and orients 3 de novo tomato genome assemblies, including the widely used M82 reference cultivar. We then demonstrate the scalability and utility of RaGOO with a pan-genome analysis of 103 Arabidopsis thaliana accessions by examining the structural variants detected in the newly assembled pseudomolecules. RaGOO is available open source at https://github.com/malonge/RaGOO .
P1.01-17 Changes in Pulmonary Function During Platinum-Doublet Chemotherapy for Lung Cancer
Authors: J. Götschke, C. Von Wachter, L. Sellmer, P. Mertsch, D. Kauffmann-Guerrero, Z. Syunyaeva, A. Tufman
Journal: Journal of Thoracic Oncology (2019)
EP1.05-05 The Optimal Sequence of Bronchial Washing and Brushing for Diagnosis of Non-Visible Lung Cancer During Non-Guided Bronchoscopy
Authors: H. Nam, C. Kim, M.J. Kim, M.H. Park, J.H. Lim, W.Y. Kim, M.K. Lee, J.H. Kim, L. Kim, J. Ryu
Journal: Journal of Thoracic Oncology (2019)
P2.04-69 Impact of Antibiotic Usage on Survival During Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer (NSCLC)
Authors: C. Hogue, T. Kuzel, J. Borgia, G. Marwaha, P. Bonomi, M.J. Fidler, M. Batus, D. Wang, P. Barry
Journal: Journal of Thoracic Oncology (2019)
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Authors: Sagar Lonial, Susanna Jacobus, Rafael Fonseca, Matthias Weiss, Shaji Kumar, Robert Z. Orlowski, Jonathan L. Kaufman, Abdulraheem M. Yacoub, Francis K. Buadi, Timothy O’Brien, Jeffrey V. Matous, Daniel M. Anderson, Robert V. Emmons, Anuj Mahindra, Lynne I. Wagner, Madhav V. Dhodapkar, S. Vincent Rajkumar
Journal: Journal of Clinical Oncology (2019)

Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma.
P2.03-37 Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial-Mesenchymal-Transition
Authors: A. Fares, S. Martins-Filho, V. Raghavan, E. Stewart, D. Ravi, J. Weiss, K. Hueniken, D. Patel, N. Pham, A. Sacher, P. Bradbury, N. Leighl, F. Shepherd, M. Tsao, G. Liu
Journal: Journal of Thoracic Oncology (2019)
Clopidogrel Pharmacogenetics — Why the Wait?
Authors: Dan M. Roden
Journal: New England Journal of Medicine (2019)

More than 3 million people annually in the United States receive prescriptions for the antiplatelet drug clopidogrel after stenting for acute coronary syndrome.1 Although genetic variants that are present in a minority of patients of European ancestry and that predict variable clopidogrel response were identified more than a decade ago, genotype-guided prescribing is not routine, in part owing to uncertain benefits of this approach as compared with universal use of newer agents. In this issue of the Journal, Claassens et al.2 report the results of the CYP2C19 Genotype-Guided Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction Patients — Patient Outcome after . . .
P2.06-14 BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi
Authors: E. Dudnik, J. Bar, T. Kuznetsov, M. Moskovitz, J. Dudnik, T. Shochat, A. Zer, D. Urban
Journal: Journal of Thoracic Oncology (2019)
P2.01-91 Exosomal Analysis of ALK Rearrangements by Spin Column with Porous Glass Filter
Authors: T. Hatta, T. Hase, N. Ozawa, N. Yogo, H. Yukawa, H. Tanaka, D. Onoshima, M. Sato, M. Hori, Y. Baba, Y. Hasegawa
Journal: Journal of Thoracic Oncology (2019)
PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: G. Middleton, S. Popat, P. Fletcher, Y. Summers, A. Greystoke, D. Gilligan, J. Cave, N. O'Rourke, A. Brewster, E. Toy, J. Spicer, J. Savage, R. Sharpe, T. Yap, C. Swanton, L. Billingham
Journal: Journal of Thoracic Oncology (2019)
P2.03-25 Assessing the Impact of Clonal Hematopoiesis in Disease Monitoring Using Targeted Cell-Free DNA (cfDNA) Sequencing Technology
Authors: S. Yaung, L. Xi, C. Woestmann, C. Ju, D. Klass, F. Casey, B. Hinzmann, C. Heussel, M. Thomas, F. Herth, T. Muley, B. Wehnl, J. Palma, X. Ma
Journal: Journal of Thoracic Oncology (2019)
Diagnosis and Management of Dementia: Review
Authors: Zoe Arvanitakis, Raj C. Shah, David A. Bennett
Journal: JAMA (2019)

<h3>Importance</h3> Worldwide, 47 million people live with dementia and, by 2050, the number is expected to increase to 131 million. <h3>Observations</h3> Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational function. In the United States, Alzheimer disease, one cause of dementia, affects 5.8 million people. Dementia is commonly associated with more than 1 neuropathology, usually Alzheimer disease with cerebrovascular pathology. Diagnosing dementia requires a history evaluating for cognitive decline and impairment in daily activities, with corroboration from a close friend or family member, in addition to a thorough mental status examination by a clinician to delineate impairments in memory, language, attention, visuospatial cognition such as spatial orientation, executive function, and mood. Brief cognitive impairment screening questionnaires can assist in initiating and organizing the cognitive assessment. However, if the assessment is inconclusive (eg, symptoms present, but normal examination findings), neuropsychological testing can help determine whether dementia is present. Physical examination may help identify the etiology of dementia. For example, focal neurologic abnormalities suggest stroke. Brain neuroimaging may demonstrate structural changes including, but not limited to, focal atrophy, infarcts, and tumor, that may not be identified on physical examination. Additional evaluation with cerebrospinal fluid assays or genetic testing may be considered in atypical dementia cases, such as age of onset younger than 65 years, rapid symptom onset, and/or impairment in multiple cognitive domains but not episodic memory. For treatment, patients may benefit from nonpharmacologic approaches, including cognitively engaging activities such as reading, physical exercise such as walking, and socialization such as family gatherings. Pharmacologic approaches can provide modest symptomatic relief. For Alzheimer disease, this includes an acetylcholinesterase inhibitor such as donepezil for mild to severe dementia, and memantine (used alone or as an add-on therapy) for moderate to severe dementia. Rivastigmine can be used to treat symptomatic Parkinson disease dementia. <h3>Conclusions and Relevance</h3> Alzheimer disease currently affects 5.8 million persons in the United States and is a common cause of dementia, which is usually accompanied by other neuropathology, often cerebrovascular disease such as brain infarcts. Causes of dementia can be diagnosed by medical history, cognitive and physical examination, laboratory testing, and brain imaging. Management should include both nonpharmacologic and pharmacologic approaches, although efficacy of available treatments remains limited.
Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL.
Authors: Pedro J. Real, Valeria Tosello, Walden Ai, Teresa Palomero, Maria Luisa Sulis, Mireia Castillo, Irene Homminga, Jules Meijerink, Carlos Cordon-Cardo, Adolfo Ferrando
Journal: Blood (2007)
P2.14-44 Tumor Mutation Burden and Efficacy of Molecular Targeted Therapy in Lung Cancer
Authors: K. Arai, T. Sakamoto, K. Yamane, Y. Hirayama, Y. Teruya, M. Yanai, N. Kinoshita, K. Yamaguchi, H. Makino, M. Kodani, T. Igishi, A. Yamasaki
Journal: Journal of Thoracic Oncology (2019)
GRP94 promotes brain metastasis by engaging pro-survival autophagy
Authors: Naiara Santana-Codina, Laia Muixí, Ruben Foj, Rebeca Sanz-Pamplona, Miriam Badia-Villanueva, Agata Abramowicz, Anna Marcé-Grau, Ana María Cosialls, Joan Gil, Ivan Archilla, Leire Pedrosa, Josep Gonzalez, Iban Aldecoa, Angels Sierra
Journal: Neuro-Oncology (2019)

GRP94 is a glucose-regulated protein critical for survival in endoplasmic reticulum stress. Expression of GRP94 is associated with cellular transformation and increased tumorigenicity in breast cancer. Specifically, overexpression of GRP94 predicts brain metastasis (BM) in breast carcinoma patients with either triple negative or ErbB2 positive tumors. The aim of this study was to understand if microenvironmental regulation of GRP94 expression might be a hinge orchestrating BM progression.GRP94 ablation was performed in a BM model BR-eGFP-CMV/Luc-V5CA1 (BRV5CA1) of breast cancer. In vitro results were validated in a dataset of 29 metastases in diverse organs from human breast carcinomas and in BM tissue from tumors of different primary origin. BM patient-derived xenografts (PDXs) were used to test sensitivity to the therapeutic approach.BMs that overexpress GRP94 as well as tumor necrosis factor receptor-associated factor 2 are more resistant to glucose deprivation by induction of anti-apoptotic proteins (B-cell lymphoma 2 and inhibitors of apoptosis proteins) and engagement of pro-survival autophagy. GRP94 ablation downregulated autophagy in tumor cells, resulting in increased BM survival in vivo. These results were validated in a metastasis dataset from human patients, suggesting that targeting autophagy might be strategic for BM prevention. Indeed, hydroxychloroquine treatment of preclinical models of BM from PDX exerts preventive inhibition of tumor growth (P < 0.001).We show that GRP94 is directly implicated in BM establishment by activating pro-survival autophagy. Disruption of this compensatory fueling route might prevent metastatic growth.
Correction to: MicroPro: using metagenomic unmapped reads to provide insights into human microbiota and disease associations
Authors: Zifan Zhu, Jie Ren, Sonia Michail, Fengzhu Sun
Journal: Genome biology (2019)

Following publication of the original paper [1], Dr. Nayfach kindly pointed out an error and the authors would like to report the following correction.
MA12.05 Genomic Analysis of Long Term Malignant Pleura Mesothelioma Patients Treated with Palliative Chemotherapy
Authors: F. Torricelli, A. Saxena, R. Nuamah, M. Neat, L. Harling, W. Ng, J. Spicer, A. Ciarrocchi, A. Bille
Journal: Journal of Thoracic Oncology (2019)
MA08.01 Analysis of PD-L1 Expression on Circulating Stromal and Tumor Cells in Lung Cancer Patients Treated with Chemoradiation Therapy and Atezolizumab
Authors: S. Lin, A. Augustyn, J. He, Y. Qiao, Z. Liao, A. Raghavakaimal, K. Gardner, J. Heymach, A. Tsao, D. Adams
Journal: Journal of Thoracic Oncology (2019)
Gholam-Ali Beski
Authors: Golnar Aref-Adib
Journal: BMJ (2019)

After qualifying as a doctor, my grandfather, Gholam-Ali Beski, set up a hospital, a school with a boarding house—providing free education to gifted children—and later a hospice. Throughout these endeavours he was supported by his wife, Shafigeh—an equally astute, hardworking woman and midwife—who would help run the hospital while taking care of their four children.

Before “wellness” was even a concept, Dr Beski recognised through curing his own medical problems that food can be both a medicine and a poison. He became initially vegetarian, then vegan, and then an advocate for a raw plant based diet. He recognised the carcinogens in meat, the toxins from animal …
David Oliver: Fear in medical practice
Authors: David Oliver
Journal: BMJ (2019)

Last week Helen Salisbury wrote in her BMJ column about the fear of getting things wrong as a GP.1 Medical practice, by its nature and the disposition of many doctors, has always entailed worry, however well trained or confident we are. But, if worry becomes more generalised anxiety or escalates to fear, the threat to our mental health or ability to function in demanding jobs seems stark.

The BMA recently published a report on what needs to change to improve NHS doctors’ working lives.2 Before reading it I’d become conscious of growing fear and anxiety, in myself and in colleagues. If I was running scared—a long serving doctor, secure in my job, with a series of national leadership roles behind me—then …
EP1.01-18 Clinical Features of Locally Advanced Lung Cancer Patients with Radiation Pneumonitis After Induction Chemoradiotherapy
Authors: K. Araki, K. Suzawa, S. Miyauchi, A. Miura, K. Namba, S. Otani, H. Yamamoto, M. Okazaki, S. Sugimoto, M. Yamane, S. Toyooka
Journal: Journal of Thoracic Oncology (2019)
Improvement of Remission Duration with Low-Dose Post-Remissional Gemtuzumab Ozogamicin (GO) in Elderly Patients with Acute Myeloid Leukemia
Authors: Filippo Marmont, Ernesta Audisio, Stefano D’Ardia, Flavia Salvi, Anna Tonso, Dario Ferrero, Alessandro Levis, Umberto Vitolo
Journal: Blood (2008)
OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
Authors: R. Govindan, M. Fakih, T. Price, G. Falchook, J. Desai, J. Kuo, J. Strickler, J. Krauss, B. Li, C. Denlinger, G. Durm, J. Ngang, H. Henary, G. Ngarmchamnanrith, E. Rasmussen, P. Morrow, D. Hong
Journal: Journal of Thoracic Oncology (2019)